News Agency
The Times Real Estate

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

  • Written by PR Newswire

--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the first quarter of 2023

--Phase I clinical trial will also determine if ASC11 needs to be boosted by ritonavir or not

--In antiviral cellular assays,...

Read more: Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

Best Apps and Tech Tools for Sailors: Navigating the Digital Seas

Whether you're a seasoned sailor or just dipping your toes into life on the water, the right tech can make a world of difference. From real-time weather updates to navigation assistance and safety tools, today’s digital landscape offers a host... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion